RedHill Biopharma Reports 2017 Third Quarter Financial Results

  • RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017
  • In addition, an underwritten public offering of the Company’s American Depositary Shares (ADSs) is scheduled to be closed today,
Posted in: Uncategorized